ESTRO 2024 - Abstract Book

S5373

Radiobiology - Tumour biology

ESTRO 2024

Keywords: Melittin, Radiosensitizer, Lung cancer

References:

1. Chhikara, B.S. and K. Parang, Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters, 2023. 10(1): p. 451.

2. Ganti, A.K., et al., Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol, 2021. 7(12): p. 1824-1832.

3. Rady, I., et al., Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett, 2017. 402: p. 16-31.

4. Socarras KM et al., Antimicrobial Activity of Bee Venom and Melittin against Borrelia burgdorferi. Antibiotics (Basel). 2017. 6(4): p. 31.

1335

Poster Discussion

Ceramides as a potential plasmatic biomarker of outcomes for localized prostate cancer

Damien Carignan 1,2 , Marine Bourgeois 3 , William Foster 4 , André-Guy Martin 4,1,2 , François Paris 3 , Eric Vigneault 1,4,2

1 CHU de Québec-Université Laval Research Centre, Oncology, Quebec, Canada. 2 Université Laval Cancer Research Center, Medicine, Quebec, Canada. 3 Nantes - Angers Cancer and Immunology Research Center, Radiobiologie et ciblage de l'endothélium, Nantes, France. 4 CHU de Quebec-Université Laval, Radio-Oncologie, Quebec, Canada

Purpose/Objective:

Prostate cancer is the most frequent cancer and the third cause of cancer death in men. If localized, most prostate cancer (PCa) treatments are effective, but about a third of the patients fail and eventually develop metastasis, castration resistance, and die from the disease. Radiotherapy (RT), delivered by external beams (EBRT) and brachytherapy, is one of the main treatment options for localized PCa. In high-risk disease, androgen deprivation therapy (ADT) combined with radiotherapy improves the outcomes. Adverse outcomes can, however, take years to occur after the initial treatment. Therefore, having a biomarker that could predict early treatment success or failure would be very valuable. Ceramides are pro-apoptotic sphingolipids that are known to be induced by ionizing radiation in cancer cells. They coordinate cellular responses to different forms of stress and influence the radiosensitivity of cells and tumors. Increased levels of plasma ceramides after radiation therapy have been previously correlated with tumor response (1,2).